Business
ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential
Expecting $19 Million Cash Income FREMONT, CA - March 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncol...
About this update from Abvc Biopharma, Inc.
[{"type":"image","caption":"","headline":"ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States","size":{"original":{"width":140,"height":78,"url":"https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X_qKvHxujBtXyrHhszohog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7","width":140,"height":78}}},{"type":"text","content":"Expecting $19 Million Cash Income","length":33,"tagName":"p"},{"type":"text","content":"FREMONT, CA - March 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, provides an update on its cash milestone payment receivables per global licensing agreements and $60 million CDMO acquisition, reinforcing its strategic positioning for long-term growth. With three major global licensing agreements across psychiatric disorders, ophthalmic medical devices, and oncology, coupled with a fully integrated pharmaceutical manufacturing facility, we believe that ABVC is well-positioned to generate revenue and expand its commercial footprint.","length":703,"tagName":"p"},{"type":"text","content":"$19 Million in Global Licensing Agreements Securing Future Cash Revenue","length":71,"tagName":"p"},{"type":"text","content":"Since 2023, ABVC has executed three global licensing agreements valued at $959 million, structured with upfront payments, milestone-based revenues, and commercialization royalties. These agreements are expected to contribute an aggregate of approximately $19 million in cash revenue in 2025, in line with ABVC's strategic financial planning.","length":345,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Partner 1 (Global MDD & ADHD Licensing Agreement) Potential $667 million licensing deal for ABVC's major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) drug candidates.","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"The MDD therapeutics market is projected to reach $14 billion by 2027, with antidepressant drug sales growing at a CAGR of 6.2%.[1]","len...